Lakefront Bio ADR कमाई रिजल्ट पिछाडा, आय चूका Q3 में
- Investing.com
तुलना करने के लिए मीट्रिक्स | LKFT | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधLKFTपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 3.4x | 30.1x | −0.2x | |
PEG अनुपात | 0.01 | 0.27 | 0.00 | |
क़ीमत/बुक | 0.6x | 4.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 2.0x | 5.3x | 2.8x | |
अपसाइड (विश्लेषक लक्ष्य) | −10.6% | 6.2% | 65.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 6.0% | 9.5% | अनलॉक करें |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.